Please login to the form below

Not currently logged in


This page shows the latest farletuzumab news and features for those working in and with pharma, biotech and healthcare.

BMS and Eisai to collaborate in deal worth up to $3.1bn

BMS and Eisai to collaborate in deal worth up to $3.1bn

Under the agreement, BMS and Eisai will co-commercialise and co-develop MORAb-202, an ADC which combines Eisai’s anti-folate receptor alpha (FRα) antibody farletuzumab and anticancer agent eribulin..

Latest news

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Menarini Biotech's abagovomab and Morphotek/ Eisai's farletuzumab have both had disappointing results in late-stage clinical trials. ... Farletuzumab had also entered global phase III trials, in combination with carboplatin and a taxane, in patients with

  • Eisai's farletuzumab fails ovarian cancer trial Eisai's farletuzumab fails ovarian cancer trial

    Farletuzumab has also been tipped as a long-term blockbuster prospect for Eisai, if it could be developed in multiple cancer indications. ... Morphotek remains committed to research to understand the potential role of farletuzumab in ovarian and other

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...